中国临床药理学与治疗学2025，Vol.30Issue(4)：570-576,7.DOI:10.12092/j.issn.1009-2501.2025.04.016
钠-葡萄糖共转运蛋白2抑制剂药动学相互作用研究进展
Research progress on pharmacokinetic interactions of sodium-glu-cose co-transporter 2 inhibitors
摘要
Abstract
Sodium-glucose co-transporter 2(SGLT2)inhibitors are a new class of oral hypoglyce-mic drugs with definite hypoglycemic effects,low risk of hypoglycemia,cardiovascular protection,and kidney benefits.In recent years,SGLT2 inhibi-tors have been widely used in clinical practice,and their interactions with other drugs have gradually attracted attention.The SGLT2 inhibitors commonly used in China's clinic include canagliflozin,dapa-gliflozin,empagliflozin,ertugliflozin and hena-gliflozin currently,they are mainly metabolized by the phase Ⅱ metabolic enzyme uridine diphos-phate glucuronosyltransferase(UGT),and various transporters are involved in the disposal of SGLT2 inhibitors in vivo.This article reviews the pharma-cokinetic characteristics of different SGLT2 inhibi-tors mentioned above,as well as their pharmacoki-netic interaction studies with various drugs such as statins,antineoplastic drugs,antimicrobials,nonste-roidal anti-inflammatory drugs and traditional Chi-nese medicine,in order to promote the safe and ra-tional use of SGLT2 inhibitors in clinical practice.关键词
钠-葡萄糖共转运蛋白2抑制剂/药代动力学/药物相互作用/尿苷二磷酸葡萄糖醛酸转移酶/转运体Key words
sodium-glucose co-transporter 2 in-hibitors/pharmacokinetics/drug-drug interaction/uridine diphosphate glucuronosyltransferase/trans-porter分类
医药卫生引用本文复制引用
邓艳茹,曹格溪,李颖,李亚静,董占军..钠-葡萄糖共转运蛋白2抑制剂药动学相互作用研究进展[J].中国临床药理学与治疗学,2025,30(4):570-576,7.基金项目
河北省自然科学基金项目(H2022307063) （H2022307063）
